Sponsored by: GE Healthcare

Molecular Imaging: Page 49

Video from ECR 2019: Thomas Beyer on going hybrid
VIENNA - How is hybrid imaging faring across Europe, and are ongoing turf battles between radiology and nuclear medicine getting resolved? We asked Thomas Beyer, PhD, MBA, to reflect on these issues and his first year as president of the European Society for Hybrid, Molecular and Translation Imaging (ESHIMT), as well as the next 12 months ahead.
February 28, 2019
2018 03 03 11 49 7594 Beyer Thomas Ecr 2018 Video 400
Ga-68 PSMA-11 PET/MRI improves prostate cancer detection
By Wayne Forrest
VIENNA - PET/MRI with the radiopharmaceutical gallium-68 (Ga-68) prostate-specific membrane antigen-11 (PSMA-11) could become a valuable tool in image-guided biopsy and for detecting significant prostate cancer, researchers reported on Wednesday at ECR 2019.
February 28, 2019
2019 02 28 22 32 4413 Pet Mri Biopsy Guidance 400 Thumb
COCIR restates need to replace old imaging equipment
By AuntMinnieEurope.com staff writers
The European Coordination Committee of the Radiological, Electromedical, and Healthcare IT Industry (COCIR) has released four new infographics at ECR 2019 emphasizing the ongoing deterioration of medical imaging equipment throughout Europe.
February 27, 2019
2019 02 28 18 06 6205 Cocir Info Ct
Be aware of artifacts to improve hybrid imaging outcomes
By Frances Rylands-Monk
Awareness of possible artifacts and pitfalls in hybrid imaging is the first step in dealing with them, ECR 2019 delegates learned in a session during the opening day of the congress. The presenters also discussed new types of problems and challenges that may occur with the clinical application of novel specific tracers.
February 26, 2019
2019 02 26 21 00 5734 2019 02 27 Ecr Today Hybrid Thumb
MILabs signs deal with German university
By AuntMinnieEurope.com staff writers
Preclinical imaging developer MILabs has signed an agreement to provide the Institute of Experimental Molecular Imaging at the Rheinisch-Westfälische Technische Hochschule Aachen University with its high-resolution hybrid optical tomography/CT system.
February 24, 2019
Spain probes anticompetitive PET practices
By AuntMinnieEurope.com staff writers
Spanish authorities have launched disciplinary proceedings against French molecular imaging firm Advanced Accelerator Applications and global nuclear medicine firm Curium for alleged anticompetition practices in Spain.
February 13, 2019
Blue Earth begins producing Axumin in Italy
By AuntMinnieEurope.com staff writers
Molecular imaging firm Blue Earth Diagnostics has competed the first commercial production of its Axumin PET radiopharmaceutical in Italy.
February 11, 2019
AuntMinnieEurope.com Molecular Imaging Insider
By Wayne Forrest
February 3, 2019
FDG-PET/CT or MRI: Which is best for HNSCC recurrence?
By Wayne Forrest
Which modality is the most appropriate choice to diagnose suspected local recurrence of head and neck squamous cell carcinoma (HNSCC)? Dutch researchers chose FDG-PET/CT over MRI in a study published in the February issue of the European Journal of Radiology.
February 3, 2019
2017 03 24 11 45 14 696 Dutch Flag 400
FET-PET gives boost to pediatric neuro-oncology
By Wayne Forrest
Danish researchers have found that fluoroethyl-tyrosine (FET)-PET can help confirm the success of surgical procedures performed on children with brain and spinal cord tumors to ensure that no residual tumor is left behind. Their study was published online on 25 January in the Journal of Nuclear Medicine.
February 3, 2019
2019 02 01 18 58 8212 Pet Mri Pedx Jnm Marner Thumb
FDG-PET/CT improves bladder cancer staging
By Wayne Forrest
Combining metabolic and morphologic data from FDG-PET/CT scans can significantly improve the detection of lymph node metastasis in patients with muscle-invasive bladder cancer before their surgery, according to a French study published online on 21 January in European Radiology.
January 30, 2019
2017 10 26 18 32 2756 Cancer Cell Yellow 400
MRI optimizes photodynamic therapy efficacy
By Tami Freeman, PhD
Photodynamic therapy uses a light-activated drug to create reactive oxygen species that kill nearby cancer cells, but its use is limited by the low penetration of light into tissue and insufficient accumulation of the photosensitizing drug in tumors. Russian researchers have devised an MRI-based method to overcome this hurdle.
January 23, 2019
2019 01 23 19 45 3806 Russia Flag 400
Previous Page
Page 49 of 121
Next Page